NCT01515969 2016-07-12
Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)
Stanford University
Phase 1 Terminated
Stanford University
Biogen
Fukushima Medical University
Fukushima Medical University
Tokyo University